A Study to Evaluate RO7566802
Phase 1
250
about 4.1 years
18+
6 sites in AL, CT, NY +3
About this study
Researchers are testing the safety, how it works in the body (pharmacokinetics), and if it helps fight cancer (activity) of a new drug called RO7566802. The trial will be given alone or with atezolizumab to people with locally advanced, recurrent, or metastatic solid tumors.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Atezolizumab
- 2.Take RO7566802
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
atezolizumab
injection (Injection)
Primary: Number of Participants with Dose-limiting Toxicity (DLTs), Percentage of Participants with Adverse Events (AEs) Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)
Secondary: Area Under the Serum Concentration Time Curve (AUC) of RO7566802, Maximum Serum Concentration (Cmax) of RO7566802, Objective Response Rate as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1), Total Clearance (CL) of RO7566802
Oncology